FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969723784> ?p ?o ?g. }

• W1969723784 endingPage "4767" @default.
• W1969723784 startingPage "4759" @default.
• W1969723784 abstract "Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different dosing regimens have never been compared head to head. The objective of the study was to investigate the relationship between mitotane dose and plasma concentration comparing two dosing regimens. This was a prospective, open-label, multicenter trial of a predefined duration of 12 weeks. Forty mitotane-naïve patients with metastatic adrenocortical carcinoma were assigned to a predefined low- or high-dose regimen by the local investigator. Thirty-two patients could be evaluated in detail. The difference in median mitotane plasma levels between both treatment groups was measured. Despite a difference in mean cumulative dose (440 ± 142 g vs 272 ± 121 g), median maximum plasma levels were not significantly different between the two groups [high dose 14.3 mg/L (range 6.3–29.7, n = 20) vs 11.3 mg/L (range 5.5–20.0, n = 12), P = .235]. Ten of 20 patients on the high-dose regimen reached plasma concentrations of 14 mg/L or greater after 46 days (range 18–81 d) compared with 4 of 12 patients on the low-dose regimen after 55 days (range 46–74 d, P = .286). All patients who reached 14 mg/L at 12 weeks displayed a level of 4.1 mg/L or greater on day 33 (100% sensitivity). There were no significant differences in frequency and severity of adverse events. Among patients not receiving concomitant chemotherapy mitotane exposure was higher in the high-dose group: 1013 ± 494 mg/L · d vs 555 ± 168 mg/L · d (P = .080). The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for combination therapy a lower dose seems reasonable." @default.
• W1969723784 created "2016-06-24" @default.
• W1969723784 creator A5002808277 @default.
• W1969723784 creator A5003946700 @default.
• W1969723784 creator A5005843927 @default.
• W1969723784 creator A5016606339 @default.
• W1969723784 creator A5030308582 @default.
• W1969723784 creator A5043328708 @default.
• W1969723784 creator A5067116958 @default.
• W1969723784 creator A5076231651 @default.
• W1969723784 creator A5081409867 @default.
• W1969723784 creator A5084197098 @default.
• W1969723784 creator A5090695853 @default.
• W1969723784 date "2013-12-01" @default.
• W1969723784 modified "2023-09-29" @default.
• W1969723784 title "Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma" @default.
• W1969723784 cites W1553784037 @default.
• W1969723784 cites W1606582049 @default.
• W1969723784 cites W1967352082 @default.
• W1969723784 cites W1967949880 @default.
• W1969723784 cites W1987174700 @default.
• W1969723784 cites W1988833634 @default.
• W1969723784 cites W1992200576 @default.
• W1969723784 cites W1995124360 @default.
• W1969723784 cites W2007102313 @default.
• W1969723784 cites W2011476238 @default.
• W1969723784 cites W2014839531 @default.
• W1969723784 cites W2042262840 @default.
• W1969723784 cites W2061915722 @default.
• W1969723784 cites W2066923659 @default.
• W1969723784 cites W2068845486 @default.
• W1969723784 cites W2079874148 @default.
• W1969723784 cites W2088755899 @default.
• W1969723784 cites W2089304791 @default.
• W1969723784 cites W2091048532 @default.
• W1969723784 cites W2095699011 @default.
• W1969723784 cites W2106503032 @default.
• W1969723784 cites W2128921375 @default.
• W1969723784 cites W2131354405 @default.
• W1969723784 cites W2134264575 @default.
• W1969723784 cites W2142711036 @default.
• W1969723784 cites W2157310187 @default.
• W1969723784 cites W2166261257 @default.
• W1969723784 cites W2167852501 @default.
• W1969723784 cites W2411320895 @default.
• W1969723784 cites W99169869 @default.
• W1969723784 doi "https://doi.org/10.1210/jc.2013-2281" @default.
• W1969723784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24057287" @default.
• W1969723784 hasPublicationYear "2013" @default.
• W1969723784 type Work @default.
• W1969723784 sameAs 1969723784 @default.
• W1969723784 citedByCount "76" @default.
• W1969723784 countsByYear W19697237842013 @default.
• W1969723784 countsByYear W19697237842014 @default.
• W1969723784 countsByYear W19697237842015 @default.
• W1969723784 countsByYear W19697237842016 @default.
• W1969723784 countsByYear W19697237842017 @default.
• W1969723784 countsByYear W19697237842018 @default.
• W1969723784 countsByYear W19697237842019 @default.
• W1969723784 countsByYear W19697237842020 @default.
• W1969723784 countsByYear W19697237842021 @default.
• W1969723784 countsByYear W19697237842022 @default.
• W1969723784 countsByYear W19697237842023 @default.
• W1969723784 crossrefType "journal-article" @default.
• W1969723784 hasAuthorship W1969723784A5002808277 @default.
• W1969723784 hasAuthorship W1969723784A5003946700 @default.
• W1969723784 hasAuthorship W1969723784A5005843927 @default.
• W1969723784 hasAuthorship W1969723784A5016606339 @default.
• W1969723784 hasAuthorship W1969723784A5030308582 @default.
• W1969723784 hasAuthorship W1969723784A5043328708 @default.
• W1969723784 hasAuthorship W1969723784A5067116958 @default.
• W1969723784 hasAuthorship W1969723784A5076231651 @default.
• W1969723784 hasAuthorship W1969723784A5081409867 @default.
• W1969723784 hasAuthorship W1969723784A5084197098 @default.
• W1969723784 hasAuthorship W1969723784A5090695853 @default.
• W1969723784 hasBestOaLocation W19697237841 @default.
• W1969723784 hasConcept C112705442 @default.
• W1969723784 hasConcept C126322002 @default.
• W1969723784 hasConcept C126894567 @default.
• W1969723784 hasConcept C151032500 @default.
• W1969723784 hasConcept C197934379 @default.
• W1969723784 hasConcept C2776694085 @default.
• W1969723784 hasConcept C2776735609 @default.
• W1969723784 hasConcept C2777288759 @default.
• W1969723784 hasConcept C2777546739 @default.
• W1969723784 hasConcept C2779384505 @default.
• W1969723784 hasConcept C2781399356 @default.
• W1969723784 hasConcept C2781413609 @default.
• W1969723784 hasConcept C71924100 @default.
• W1969723784 hasConcept C90924648 @default.
• W1969723784 hasConceptScore W1969723784C112705442 @default.
• W1969723784 hasConceptScore W1969723784C126322002 @default.
• W1969723784 hasConceptScore W1969723784C126894567 @default.
• W1969723784 hasConceptScore W1969723784C151032500 @default.
• W1969723784 hasConceptScore W1969723784C197934379 @default.
• W1969723784 hasConceptScore W1969723784C2776694085 @default.
• W1969723784 hasConceptScore W1969723784C2776735609 @default.
• W1969723784 hasConceptScore W1969723784C2777288759 @default.

• next